Sharon P. Vanloo
Impact in
- Cancer Research top 5%
- Cancer Genomics and Diagnostics
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Lung Cancer Research Studies
Papers in
-
- Cancer Genomics and Diagnostics 11
-
- SARS-CoV-2 and COVID-19 Research 2
- SARS-CoV-2 detection and testing 1
- Journals
- Nature (6 papers)Nature Medicine (3 papers)Nature Genetics (3 papers)Nature Cancer (3 papers)Nature Communications (2 papers)
- Partner nations
- United Kingdom
In The Last Decade
Sharon P. Vanloo
21 papers receiving 1.9k citations
Sharon P. Vanloo's Hit Papers
Peers
Comparison fields: 5 of 105
- Cancer Research 526
- Oncology 478
- Pulmonary and Respiratory Medicine 488
- Health, Toxicology and Mutagenesis 172
- Modeling and Simulation 51
Countries citing papers authored by Sharon P. Vanloo
This map shows the geographic impact of Sharon P. Vanloo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sharon P. Vanloo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sharon P. Vanloo more than expected).
Fields of papers citing papers by Sharon P. Vanloo
This network shows the impact of papers produced by Sharon P. Vanloo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sharon P. Vanloo. The network helps show where Sharon P. Vanloo may publish in the future.
No co-authors to show.
All Works
Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Lung adenocarcinoma promotion by air pollutants Hit paper breakdown → | 2023 | 546 |
| 2 | Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA Hit paper breakdown → | 2023 | 268 |
| 3 | The evolution of lung cancer and impact of subclonal selection in TRACERx Hit paper breakdown → | 2023 | 192 |
| 4 | The evolution of non-small cell lung cancer metastases in TRACERx Hit paper breakdown → | 2023 | 159 |
| 5 | 2020 | 158 | |
| 6 | Genomic–transcriptomic evolution in lung cancer and metastasis Hit paper breakdown → | 2023 | 140 |
| 7 | 2022 | 93 | |
| 8 | 2023 | 90 | |
| 9 | 2023 | 72 | |
| 10 | Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma Hit paper breakdown → | 2025 | 65 |
| 11 | 2024 | 29 | |
| 12 | 2024 | 29 | |
| 13 | 2024 | 27 | |
| 14 | 2020 | 25 | |
| 15 | 2024 | 23 | |
| 16 | 2025 | 15 | |
| 17 | 2020 | 13 | |
| 18 | 2025 | 5 | |
| 19 | 2025 | 4 | |
| 20 | 2025 | 3 |
About Sharon P. Vanloo
Sharon P. Vanloo is a scholar working on Cancer Research, Infectious Diseases, Oncology, Immunology and Modeling and Simulation, having authored 21 papers that have together received 2k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (11 papers), Cancer Immunotherapy and Biomarkers (3 papers), Lung Cancer Treatments and Mutations (2 papers), T-cell and B-cell Immunology (2 papers), SARS-CoV-2 and COVID-19 Research (2 papers), SARS-CoV-2 detection and testing (1 paper), Epigenetics and DNA Methylation (1 paper) and COVID-19 epidemiological studies (1 paper). The work is most often cited by research in Cancer Research (526 citations), Oncology (478 citations), Pulmonary and Respiratory Medicine (488 citations), Health, Toxicology and Mutagenesis (172 citations) and Modeling and Simulation (51 citations). Sharon P. Vanloo has collaborated with scholars based in United Kingdom. Their work appears in journals such as Nature, Nature Medicine, Nature Genetics, Nature Cancer and Nature Communications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.